含皂苷佐剂的亚单位疫苗增强对中东呼吸综合征冠状病毒的体液与细胞免疫
为应对病死率高于34%的中东呼吸综合征冠状病毒(MERS-CoV)疫情,研究者设计含三聚化基序的重组S1蛋白(S1-Fd)亚单位疫苗,联合不同佐剂在小鼠中评估免疫原性与保护性免疫。结果显示,免疫后野生型与人DPP4转基因小鼠血清含可中和MERS-CoV感染的S1特异性抗体;S1-Fd联合皂苷类QS-21佐剂可在小鼠中提供长期体液免疫与细胞免疫。
要点
- MERS-CoV疫情病死率高于34%,需开发有效疫苗。
- S1-Fd联合QS-21佐剂可在小鼠中诱导长期体液与细胞免疫。
- 免疫小鼠血清含可中和MERS-CoV感染的S1特异性抗体。
核心结论
- 三聚化S1蛋白对MERS-CoV疫苗开发有意义,QS-21佐剂可诱导强而持久的记忆T细胞应答。
研究设计与样本
- 研究设计为动物实验,对象为野生型小鼠与人DPP4转基因小鼠,评估S1-Fd亚单位疫苗联合多种佐剂的免疫原性与保护性免疫应答。
主要发现
- 免疫后野生型与人DPP4转基因小鼠血清含S1特异性抗体,可中和敏感细胞中的MERS-CoV感染。
- S1-Fd联合皂苷类QS-21佐剂在小鼠中提供长期体液免疫与细胞免疫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks have constituted a public health issue with drastic mortality higher than 34%, necessitating the development of an effective vaccine. During MERS-CoV infection, the trimeric spike protein on the viral envelope is primarily responsible for attachment to host cellular receptor, dipeptidyl peptidase 4 (DPP4). With the goal of generating a protein-based prophylactic, we designed a subunit vaccine comprising the recombinant S1 protein with a trimerization motif (S1-Fd) and examined its immunogenicity and protective immune responses in combination with various adjuvants. We found that sera from immunized wild-type and human DPP4 transgenic mice contained S1-specific antibodies that can neutralize MERS-CoV infection in susceptible cells. Vaccination with S1-Fd protein in combination with a saponin-based QS-21 adjuvant provided long-term humoral as well as cellular immunity in mice. Our findings highlight the significance of the trimeric S1 protein in the development of MERS-CoV vaccines and offer a suitable adjuvant, QS-21, to induce robust and prolonged memory T cell response.
引用
- Chang CC, Algaissi A, Lai CC, et al. Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus. Vaccine. 2023. PMID: 37085450. doi:10.1016/j.vaccine.2023.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。